Just days after its share price went south by 50%, UK biotech Midatech Pharma PLC has detailed plans that may save the development of its carcinoid cancer drug candidate. The arrangement will see a Chinese drug distributor take majority ownership of the firm.
In a trading update last week, the Oxford-based company said it had “very limited cash to enable it to continue as a going concern” and “will urgently look to conclude...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?